The medical deferoxamine mesylate market size has grown strongly in recent years. It will grow from $1.28 billion in 2025 to $1.38 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increasing prevalence of transfusion-dependent anemia, rising incidence of thalassemia and sickle cell disease, expansion of hospital treatment protocols, improved diagnosis of iron overload disorders, availability of chelation therapies.
The medical deferoxamine mesylate market size is expected to see strong growth in the next few years. It will grow to $1.91 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing development of alternative chelation drugs, rising focus on patient-friendly formulations, expansion of rare disease treatment programs, growing investments in specialty pharmaceuticals, increasing awareness of iron toxicity management. Major trends in the forecast period include increasing demand for iron chelation therapies, rising use of injectable deferoxamine formulations, expansion of hospital-based iron overload treatment, growing focus on chronic transfusion management, enhanced emphasis on treatment compliance.
The growing prevalence of iron overload disorders is anticipated to drive the expansion of the medical deferoxamine mesylate market in the coming years. These disorders, characterized by an excessive accumulation of iron in the body, can result from genetic factors, frequent blood transfusions, or certain chronic illnesses. The increased use of long-term blood transfusions for managing chronic hemoglobinopathies, alongside improved patient survival rates, has contributed to a larger population at risk, thereby increasing the incidence of iron overload disorders. Medical deferoxamine mesylate plays a crucial role in treating these conditions by removing excess iron, preventing organ damage, and assisting patients with conditions such as thalassemia and hemochromatosis. For example, a March 2023 report from the Electronic Journal of General Medicine noted that 10.73% of patients (1,085) had alpha-thalassemia, 2.24% (227) had beta-thalassemia, and 0.29% (29) had both mutations. Thus, the rising prevalence of iron overload disorders is driving the growth of the medical deferoxamine mesylate market.
Key players in the medical deferoxamine mesylate market are focusing on developing generic versions of drugs to improve patient access, lower treatment costs, and enhance their competitive standing in the global market. Generic drugs, which are more affordable alternatives to branded medicines, contain the same active ingredients and provide the same therapeutic benefits once the original patent expires. For example, in January 2023, Pharmascience Inc., a Canadian pharmaceutical company, introduced PRpms-DEFERASIROX (TYPE J), a cost-effective substitute for Jadenu. This medication, used to treat chronic iron overload in both children and adults with anemia or thalassemia, offers the same safety and efficacy in 90 mg and 360 mg tablet forms.
In September 2024, Mitem Pharma, a French pharmaceutical company, acquired the global rights to DESFERAL (deferoxamine mesylate) from Novartis AG for an undisclosed amount. This acquisition strengthens Mitem Pharma’s position in the iron chelation therapy market and enhances its portfolio with a well-established treatment for managing iron overload disorders. Novartis AG, a Swiss-based pharmaceutical company, is known for producing therapeutic drugs for rare diseases.
Major companies operating in the medical deferoxamine mesylate market are Novartis AG, Merck KGaA, Teva Pharmaceutical Industries Inc., Intas Pharmaceuticals Ltd., Fresenius Kabi AG, Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., Hospira Inc., Manus Aktteva Biopharma LLP, Merit Pharmaceuticals Inc., Aurobindo Pharma Ltd., Cipla Limited, Cadila Healthcare Ltd., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Pharmacosmos A/S, American Regent Inc., Ferring Pharmaceuticals, Sandoz Inc., Emcure Pharmaceuticals Ltd., Akorn Incorporated, Dr. Reddy’s Laboratories Ltd.
North America was the largest region in the medical deferoxamine mesylate market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medical deferoxamine mesylate market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medical deferoxamine mesylate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the medical deferoxamine mesylate market by increasing costs of imported pharmaceutical intermediates, chelation compounds, sterile injectables manufacturing equipment, and packaging materials. Drug manufacturers in North America and Europe are most affected due to dependence on global raw material sourcing, while Asia-Pacific faces pricing pressure on generic drug exports. These tariffs are contributing to higher treatment costs and procurement challenges. However, they are also supporting localized pharmaceutical manufacturing, domestic API production, and stronger regional supply chain control for essential chelation therapies.
The medical deferoxamine mesylate market research report is one of a series of new reports that provides medical deferoxamine mesylate market statistics, including medical deferoxamine mesylate industry global market size, regional shares, competitors with a medical deferoxamine mesylate market share, detailed medical deferoxamine mesylate market segments, market trends and opportunities, and any further data you may need to thrive in the medical deferoxamine mesylate industry. This medical deferoxamine mesylate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Medical deferoxamine mesylate is a medication used to remove excess iron from the body. It is primarily prescribed to individuals with dangerously high iron levels, often due to frequent blood transfusions. The drug binds to the excess iron, enabling the body to safely eliminate it through urine or bile.
The main types of medical deferoxamine mesylate products include injectable, oral, and topical formulations. Injectable products are delivered into the body using a needle and syringe, with administration methods including subcutaneous, intramuscular, and intravenous routes. These products are distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Key applications of deferoxamine mesylate include the treatment of iron overload disorders, aluminum toxicity, and acute iron poisoning. It is primarily used by hospitals and clinics among other healthcare providers.
The medical deferoxamine mesylate market consists of sales of infusion pumps, syringes, and generic version of drug. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The medical deferoxamine mesylate market size is expected to see strong growth in the next few years. It will grow to $1.91 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing development of alternative chelation drugs, rising focus on patient-friendly formulations, expansion of rare disease treatment programs, growing investments in specialty pharmaceuticals, increasing awareness of iron toxicity management. Major trends in the forecast period include increasing demand for iron chelation therapies, rising use of injectable deferoxamine formulations, expansion of hospital-based iron overload treatment, growing focus on chronic transfusion management, enhanced emphasis on treatment compliance.
The growing prevalence of iron overload disorders is anticipated to drive the expansion of the medical deferoxamine mesylate market in the coming years. These disorders, characterized by an excessive accumulation of iron in the body, can result from genetic factors, frequent blood transfusions, or certain chronic illnesses. The increased use of long-term blood transfusions for managing chronic hemoglobinopathies, alongside improved patient survival rates, has contributed to a larger population at risk, thereby increasing the incidence of iron overload disorders. Medical deferoxamine mesylate plays a crucial role in treating these conditions by removing excess iron, preventing organ damage, and assisting patients with conditions such as thalassemia and hemochromatosis. For example, a March 2023 report from the Electronic Journal of General Medicine noted that 10.73% of patients (1,085) had alpha-thalassemia, 2.24% (227) had beta-thalassemia, and 0.29% (29) had both mutations. Thus, the rising prevalence of iron overload disorders is driving the growth of the medical deferoxamine mesylate market.
Key players in the medical deferoxamine mesylate market are focusing on developing generic versions of drugs to improve patient access, lower treatment costs, and enhance their competitive standing in the global market. Generic drugs, which are more affordable alternatives to branded medicines, contain the same active ingredients and provide the same therapeutic benefits once the original patent expires. For example, in January 2023, Pharmascience Inc., a Canadian pharmaceutical company, introduced PRpms-DEFERASIROX (TYPE J), a cost-effective substitute for Jadenu. This medication, used to treat chronic iron overload in both children and adults with anemia or thalassemia, offers the same safety and efficacy in 90 mg and 360 mg tablet forms.
In September 2024, Mitem Pharma, a French pharmaceutical company, acquired the global rights to DESFERAL (deferoxamine mesylate) from Novartis AG for an undisclosed amount. This acquisition strengthens Mitem Pharma’s position in the iron chelation therapy market and enhances its portfolio with a well-established treatment for managing iron overload disorders. Novartis AG, a Swiss-based pharmaceutical company, is known for producing therapeutic drugs for rare diseases.
Major companies operating in the medical deferoxamine mesylate market are Novartis AG, Merck KGaA, Teva Pharmaceutical Industries Inc., Intas Pharmaceuticals Ltd., Fresenius Kabi AG, Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., Hospira Inc., Manus Aktteva Biopharma LLP, Merit Pharmaceuticals Inc., Aurobindo Pharma Ltd., Cipla Limited, Cadila Healthcare Ltd., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Pharmacosmos A/S, American Regent Inc., Ferring Pharmaceuticals, Sandoz Inc., Emcure Pharmaceuticals Ltd., Akorn Incorporated, Dr. Reddy’s Laboratories Ltd.
North America was the largest region in the medical deferoxamine mesylate market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medical deferoxamine mesylate market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medical deferoxamine mesylate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the medical deferoxamine mesylate market by increasing costs of imported pharmaceutical intermediates, chelation compounds, sterile injectables manufacturing equipment, and packaging materials. Drug manufacturers in North America and Europe are most affected due to dependence on global raw material sourcing, while Asia-Pacific faces pricing pressure on generic drug exports. These tariffs are contributing to higher treatment costs and procurement challenges. However, they are also supporting localized pharmaceutical manufacturing, domestic API production, and stronger regional supply chain control for essential chelation therapies.
The medical deferoxamine mesylate market research report is one of a series of new reports that provides medical deferoxamine mesylate market statistics, including medical deferoxamine mesylate industry global market size, regional shares, competitors with a medical deferoxamine mesylate market share, detailed medical deferoxamine mesylate market segments, market trends and opportunities, and any further data you may need to thrive in the medical deferoxamine mesylate industry. This medical deferoxamine mesylate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Medical deferoxamine mesylate is a medication used to remove excess iron from the body. It is primarily prescribed to individuals with dangerously high iron levels, often due to frequent blood transfusions. The drug binds to the excess iron, enabling the body to safely eliminate it through urine or bile.
The main types of medical deferoxamine mesylate products include injectable, oral, and topical formulations. Injectable products are delivered into the body using a needle and syringe, with administration methods including subcutaneous, intramuscular, and intravenous routes. These products are distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Key applications of deferoxamine mesylate include the treatment of iron overload disorders, aluminum toxicity, and acute iron poisoning. It is primarily used by hospitals and clinics among other healthcare providers.
The medical deferoxamine mesylate market consists of sales of infusion pumps, syringes, and generic version of drug. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Medical Deferoxamine Mesylate Market Characteristics
3. Medical Deferoxamine Mesylate Market Supply Chain Analysis
4. Global Medical Deferoxamine Mesylate Market Trends and Strategies
5. Medical Deferoxamine Mesylate Market Analysis of End Use Industries
7. Global Medical Deferoxamine Mesylate Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Medical Deferoxamine Mesylate Total Addressable Market (TAM) Analysis for the Market
9. Medical Deferoxamine Mesylate Market Segmentation
10. Medical Deferoxamine Mesylate Market Regional and Country Analysis
11. Asia-Pacific Medical Deferoxamine Mesylate Market
12. China Medical Deferoxamine Mesylate Market
13. India Medical Deferoxamine Mesylate Market
14. Japan Medical Deferoxamine Mesylate Market
15. Australia Medical Deferoxamine Mesylate Market
16. Indonesia Medical Deferoxamine Mesylate Market
17. South Korea Medical Deferoxamine Mesylate Market
18. Taiwan Medical Deferoxamine Mesylate Market
19. South East Asia Medical Deferoxamine Mesylate Market
20. Western Europe Medical Deferoxamine Mesylate Market
21. UK Medical Deferoxamine Mesylate Market
22. Germany Medical Deferoxamine Mesylate Market
23. France Medical Deferoxamine Mesylate Market
24. Italy Medical Deferoxamine Mesylate Market
25. Spain Medical Deferoxamine Mesylate Market
26. Eastern Europe Medical Deferoxamine Mesylate Market
27. Russia Medical Deferoxamine Mesylate Market
28. North America Medical Deferoxamine Mesylate Market
29. USA Medical Deferoxamine Mesylate Market
30. Canada Medical Deferoxamine Mesylate Market
31. South America Medical Deferoxamine Mesylate Market
32. Brazil Medical Deferoxamine Mesylate Market
33. Middle East Medical Deferoxamine Mesylate Market
34. Africa Medical Deferoxamine Mesylate Market
36. Medical Deferoxamine Mesylate Market Competitive Landscape and Company Profiles
37. Medical Deferoxamine Mesylate Market Other Major and Innovative Companies
40. Medical Deferoxamine Mesylate Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Medical Deferoxamine Mesylate Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses medical deferoxamine mesylate market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for medical deferoxamine mesylate? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The medical deferoxamine mesylate market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Injectable; Parenteral Formulations2) By Route Of Administration: Subcutaneous; Intramuscular; Intravenous
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Others Distribution Channel
4) By Application: Iron Overload Disorders; Aluminum Toxicity; Acute Iron Poisoning; Other Applications
5) By End-User: Hospitals; Clinics
Subsegments:
1) By Injectable: Intramuscular (IM); Intravenous (IV); Subcutaneous (SC)2) By Parenteral Formulations: Intravenous; Subcutaneous; Intramuscular
Companies Mentioned: Novartis AG; Merck KGaA; Teva Pharmaceutical Industries Inc.; Intas Pharmaceuticals Ltd.; Fresenius Kabi AG; Apotex Inc.; Lupin Limited; Glenmark Pharmaceuticals Ltd.; Torrent Pharmaceuticals Ltd.; Wockhardt Ltd.; Hospira Inc.; Manus Aktteva Biopharma LLP; Merit Pharmaceuticals Inc.; Aurobindo Pharma Ltd.; Cipla Limited; Cadila Healthcare Ltd.; Sun Pharmaceutical Industries Ltd.; Alkem Laboratories Ltd.; Pharmacosmos A/S; American Regent Inc.; Ferring Pharmaceuticals; Sandoz Inc.; Emcure Pharmaceuticals Ltd.; Akorn Incorporated; Dr. Reddy’s Laboratories Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Medical Deferoxamine Mesylate market report include:- Novartis AG
- Merck KGaA
- Teva Pharmaceutical Industries Inc.
- Intas Pharmaceuticals Ltd.
- Fresenius Kabi AG
- Apotex Inc.
- Lupin Limited
- Glenmark Pharmaceuticals Ltd.
- Torrent Pharmaceuticals Ltd.
- Wockhardt Ltd.
- Hospira Inc.
- Manus Aktteva Biopharma LLP
- Merit Pharmaceuticals Inc.
- Aurobindo Pharma Ltd.
- Cipla Limited
- Cadila Healthcare Ltd.
- Sun Pharmaceutical Industries Ltd.
- Alkem Laboratories Ltd.
- Pharmacosmos A/S
- American Regent Inc.
- Ferring Pharmaceuticals
- Sandoz Inc.
- Emcure Pharmaceuticals Ltd.
- Akorn Incorporated
- Dr. Reddy’s Laboratories Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.38 Billion |
| Forecasted Market Value ( USD | $ 1.91 Billion |
| Compound Annual Growth Rate | 8.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
